You are here


February 6, 2015
New Cohort Study Begins in Mozambique

MHRP recently began a new cohort study, RV363, to assess the incidence of HIV and the willingness of adults to participate in future HIV vaccine trials in Mozambique. The study will determine incidence in men and women aged 18–35 in both Maputo and Beira. 

The retention rate of the enrolled cohort will be assessed over a 2-year follow-up period with a quarterly follow-up visit. RV363...

January 29, 2015
At the Frontlines of an Epidemic: Combating Ebola in Liberia

Last fall, CDR Jennifer Malia, DrPH, MHRP’s Assistant Chief of the Department of Laboratory Diagnostics and Monitoring, jumped at the opportunity to deploy to Liberia and treat Ebola patients. Malia spent more than a month in Monrovia, setting up a dedicated Ebola Treatment Center for health care workers and running a laboratory.

When the Public Health Service’s Chief Medical Officer...

December 23, 2014
Study confirms Ebola and Marburg Virus DNA Vaccines are Safe and Immunogenic in Africa

Results from the first Ebola vaccine clinical trial conducted in Africa (in 2009-2010) reveal a vaccine candidate produces the same immune response seen in the United States in an African setting. Importantly, this vaccine candidate is a precursor to candidates currently under evaluation for potential testing in West Africa. The findings of this 2009-2010 study, published online today in The...

December 8, 2014
New Journal of Virus Eradication Launches Today

MHRP's Dr. Jintanat Anaworanich is the Editor in Chief of a new scientific journal that aims to advance research in viral remission. The Journal of Virus Eradication (JVE) encompasses all aspects of viral disease including basic, clinical, behavioral, social and ethical research.  

For the inaugural issue, Dr. Anaworanich co-authored an editorial on the current direction and future...

December 1, 2014
World AIDS Day: Accelerating the Hunt for An Effective HIV Vaccine

On World AIDS Day (Dec. 1), two leading HIV researchers are calling on the global community to renew the sense of urgency around developing a safe and effective vaccine against HIV/AIDS. In an editorial published in the scientific journal Cell, US Army Col. Nelson Michael at the Walter Reed Army Institute of Research (WRAIR) and Dan Barouch, a Harvard Medical School Professor at Beth Israel...

December 1, 2014
Dr. Jintanat Ananworanich Recieves Princess Soamsawali's Award in Thailand

On World AIDS Day, MHRP’s Dr.Jintanat Ananworanich was given an award from Her Royal Highness Princess Soamsawali for her major contributions to the advancement of HIV care and research in Thailand.

The “Thian Song Jai” (candle light in the mind) ceremony has been organized by the Thai Red Cross each year on World AIDS Day for the past 23 years to increase the public’s awareness of HIV/...

November 20, 2014
In Uganda, MHRP Researchers Find Viral Burden to be Primary Predictor of HIV Disease Progression

New findings published this week in the Journal of Infectious Diseases found HIV-1 viral load and subtype to be the primary predictors of disease progression in rural Uganda. 

The findings from the collaborative study, lead by researchers at the U.S. Military HIV Research Program (MHRP), is contrary to current understanding that T-cell activation predicts disease progression...

October 29, 2014
In South Africa, RV144 HIV Vaccine Regimen Induces Immune Responses Similiar to Those Seen in Thailand

The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa. The results from the trial, called HVTN 097, bode...

October 23, 2014
Pox-Protein Public-Private Partnership

In 2009, the RV144 Thai vaccine trial provided the first evidence in humans that a safe and effective preventive HIV vaccine is possible. Although efficacy was 31.2% at the end of the study, there was a higher early effect (60%) at 12 months. The Pox-Protein Public-Private Partnership (P5) is a diverse group of organizations committed to building on the success of the RV144 HIV vaccine trial...